Akums Drugs and Pharmaceuticals has signed an agreement with one of the global pharma companies for manufacture and supply of selected pharmaceutical formulations in the European Market.

Akums group will manufacture and supply multiple SKUs of oral liquid formulation to be marketed in multiple European countries by the company.

This is in line with Akums growth objective of expanding in European and other regulated markets. The commercial supply of these products from Akums will commence in 2027 till 2032. Akums group will also initiate European approvals of its oral liquid site which it intends to leverage to manufacture these products. The approval of the site and the product dossiers is expected to be received by 2026.

Akums already has 2 of its sites (Injectable and Oral Solids) approved by the European regulators. The composite value of the agreement is approximately Euro 200 million (approximately INR 1,760 crores).

The company will receive an upfront payment of Euro 100 million (INR 880 crores) for product development and site approval from European authorities.

Speaking on this development, Sanjeev Jain, Managing Director, Akums said, “It gives us immense pleasure to enter into a strategic collaboration to manufacture and supply a globally renowned brand for one of the largest multinational pharma companies. This opens doors for us to further expand our footprints in regulated markets and replicate the domestic CDMO success globally.”

Sandeep Jain, Managing Director, Akums said, “These products are currently being manufactured in Europe. Manufacturing these products in India opens further collaboration opportunities with other global pharma companies to optimize their manufacturing costs and make their supply chain robust. This association is the testimony of our manufacturing excellence and our world class R&D capabilities. With this, we will add one more dosage form in our portfolio, which can be offered in the European market. Akums already has a European approved facility for tablets, hard gelatin capsules, sachets, ampoules, vials, eye-drops and dry powder injection.”